Stem Cell Theranostics is a biotechnology company using stem cells to treat cardiovascular diseases that is headquartered in Redwood City, California and was founded in 2013 by Anderw Lee.
The company seeks to address patient-specific pathophysiology based on the patient’s genetic profile. The company has a relationship with Stanford Cardiovascular Institute with which they developed their discovery platform that can be used to develop genetically-targeted therapies while also addressing cardiotoxicity.
Divya Nag and fellow student Andrew Lee started Stem Cell Theranostics with their professors. Nag is no longer with Stem Cell Theranostics, and has started StartX Med, a medical arm of Standford Student Enterprises Labs and now works for Apple in the Health Special Projects section.
On January 1, 2014 Stem Cell Theranostics completed their series A funding round with $5.5 million in funding from Bill Marcus.
Timeline
Funding Rounds
SBIR/STTR Awards
Patents
Further Resources
Stem Cell Theranostics and Thermo Fisher Scientific Announce Collaboration to Advance Cardiomyopathy Disease Modeling Workflows
Stem Cell Theranostics Inc
Web
stem cell theranostics Archives - Stem Cell Podcast
August 18, 2015
Stem Cell Theranostics secures "freedom to operate" in IP deal with GE Healthcare
Gareth Mcdonald
Web